Download Poster (714 KB)
Triple-negative breast cancer (TNBC) is an aggressive form of subtype breast cancer and there are currently new treatments being discovered such as the combination of immunotherapy and chemotherapy. In immunotherapy against triple-negative breast cancer, checkpoint inhibitors like PD-1/PD-L1 treat TNBC by blocking the “off” signal that prevents T-cells from killing cancer cells. As a group, we conducted a meta-narrative review collecting results from primary sources such as clinical trials and human experimental studies to support our research question on how PD-L1 inhibitor treatments compare to other treatments in patients with TNBC. The review included articles searched from Embase, Pubmed, EMBASE, and Cochrane Library for randomized controlled trials, clinical trials, and case studies published within 5 years. The articles relate to PD-1/PD-L1 inhibitors combined with chemotherapy or PD-L1 immunotherapy for triple-negative breast cancer. The results found that PD-L1 immunotherapy treatment in combination with other forms of traditional cancer therapy, such as radiation and chemotherapy, had a slightly significant positive response. However, the treatment was overwhelmingly successful in patients who exhibited PD-L1 positive TNBC compared to patients who were PD-L1 negative. Secondly, and a major concern for immunotherapy treatment is the adverse events, potentially developing autoimmune diseases. From the articles pulled, there seemed to be no new adverse events that developed for patients outside the standard toxic effects found from radiation and chemotherapy treatment.
Triple-negative breast cancer, PD-1/PD-L1, Immunotherapy, Meta-Narrative review
Biology | Immunology and Infectious Disease | Immunotherapy | Life Sciences | Other Immunology and Infectious Disease
Lazo, Hannah; Harris, Tyler; Truong, Hao; and Masroor, Alina, "Meta-Narrative Review of PD-L1 by immunotherapy on Triple-Negative Breast Cancer" (2023). Research Methods Poster Session 2023. 5.